J.Jpn. Surg. Soc.. 124(3): 246-252, 2023

---

Feature topic

CURRENT STATUS AND FUTURE PROSPECTS OF STRATIFIED TREATMENT IN NON-SMALL CELL LUNG CANCER

Progress in the treatment of non-small cell lung cancer has been remarkable and treatment options are diversifying. The prognosis of lung cancer is predicted by TNM classification, and therefore treatment is decided based on clinical stage. Surgery is the standard treatment for early-stage lung cancer. The results of several clinical trials, especially from Japan, have shown the effectiveness of limited resection such as segmentectomy or wedge resection. In addition, the recent approval of adjuvant therapy using molecular-targeted drugs and immune checkpoint molecular inhibitors was a turning point in the perioperative treatment of lung cancer. For stage Ⅳ lung cancer patients, targeted therapy is the first choice for those with driver gene mutations or translocations. Immune checkpoint inhibitors are considered depending on PD-L1 expression status. Because of the multiple treatment options available, treatment decisions during multidisciplinary conferences among surgeons, physicians, radiologists, and pathologists are increasingly recommended. It is important to communicate with patients to decide on their treatment, and shared decision making is becoming more important.

---

---

To read the PDF file you will need Adobe Reader installed on your computer.